Omeros | OMER - Operating Profit


Omeros reported $-35.41M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Adma Biologics USD 51.01M 8.21M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Immunic USD -25.73M 2.91M Sep/2024
Insmed USD -261.35M 7.48M Sep/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
MacroGenics USD 18.64M 55.4M Sep/2025
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 13.15M 2.92M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Rockwell Medical USD 515K 1.84M Jun/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025
Xoma USD -15.64M 5.56M Sep/2024